Find out more about the validation of biomarkers in this interview with Hanna Ritzén, Managing Director Research and Development at Mercodia AB (Uppsala, Sweden).
In this interview, Allena Ji (Sanofi Genzyme; MA, USA) discusses the advantages and challenges of using triple quadrupole mass spectrometry, the challenges associated with increasing biomarker assay sensitivity and how the field may be regulated and standardized.
In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.
In this interview, Natasha Savoie (Co-author and WRIB team member) discusses the publication of the decennial index of the White Papers in Bioanalysis.
In this expert interview, William Mylott discusses developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers.
This infographic presents key results from the large molecule quantification by LC–MS survey.
Learn more about the pros and cons of investing in new technologies or sticking with more traditional techniques, as well as about the key questions that should be considered before making the decision. In this infographic, we investigate the pros and cons of utilizing four different technologies available for large molecule analysis: colorimetric ELISA, Meso-Scale Diagnostics, Time Resolved Fluorescence and Quanterix Simoa.
In this interview, Robert Durham gives an overview of the new Gyrolab® xPand from Gyros Protein Technologies, presented at WRIB this year.